StreetAlpha.app
Home › Stocks › MAZE

Maze Therapeutics, Inc. (MAZE)

Healthcare
$31.37
▼ −3.27%
LAST CLOSE · NOV 20

Maze Therapeutics develops small molecule drugs for kidney and metabolic diseases and has no approved products yet. It last closed at $31.37 on Nov 20, down 3.27% on the day. The next earnings report for MAZE is expected around Wed, Mar 24, 2027. For the quarter ended Sep 2026, MAZE reported EPS of -$0.79 on revenue of $0. Over its last 8 reports the stock moved an average of 6.5% the session after earnings. Over the last 12 months MAZE insiders bought $0 of stock on the open market and sold $25.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is MAZE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MAZE.

Key Stats

Last 12 months
Results
Net income
−$151.5M
EPS (diluted)
−$2.62
Free cash flow
−$115.3M
Valuation
Market cap
$1.7B
54.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$154.2M
At Sep 30
Debt
$39.1M
At Sep 30
Shareholder equity
$428.5M
Shares outstanding
54.7M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $52.2M$52.2MFY2024FY2025: −$131.1M−$131.1MFY2025

From MAZE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · Time not announced
Reported EPS
-$0.79
Quarter ended Sep 2026
Year ago EPS
-$0.66
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.42Dec '24Mar 2025: -$1.15Mar '25Jun 2025: -$0.77Jun '25Sep 2025: -$0.66Sep '25Dec 2025: -$0.60Dec '25Mar 2026: -$0.45Mar '26Jun 2026: -$0.76Jun '26Sep 2026: -$0.79Sep '26Latest -$0.79
Revenue by quarter
Dec 2024: $0Dec '24Jun 2025: $0Jun '25Mar 2026: $20.0MMar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How MAZE moved after its last 8 reports
Average move the session after a report ±6.5%
Nov 9, 2026After the close+1.6%
Aug 11, 2026After the close+0.8%
May 12, 2026After the close+4.6%
Mar 25, 2026Time not announced−35.2%
Nov 6, 2025After the close−3.5%
Aug 12, 2025After the close−1.0%
May 14, 2025After the close+2.1%
Mar 31, 2025Time not announced−3.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MAZEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MAZE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MAZE

Technical Analysis

MAZE · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 1% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the 200 day average at $31.02, and the nearest resistance the Pivot at $31.68.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 6.3%/day
Key levels
$53.6552 week high+71.0%
$33.0020 day average+5.2%
$32.63Swing high (Oct 29)+4.0%
$32.49Pivot R1+3.6%
$31.68Pivot+1.0%
$31.37Last close
$31.02200 day average−1.1%
$30.57Pivot S1−2.6%
$29.75Swing low (Nov 2)−5.2%
$29.3950 day average−6.3%
$28.84100 day average−8.1%
$21.9552 week low−30.0%
Indicators
RSI (14)47.47Middle of its rangeNeutral
MACD0.85Below its signal lineBearish
Stochastic23.6Middle of its rangeNeutral
ADX (14)24.2Weak trend
Williams %R-83.1Oversold below −80, overbought above −20Oversold
CCI (20)-60.7Oversold below −100, overbought above 100Neutral
Rate of change−8.3%Change over 10 sessionsBearish
ATR (14)$1.98Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for MAZE

What happened before

See how MAZE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for MAZEHow many large options trades hit MAZE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MAZE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲83 buying vs 63 selling
  • ▲Held by funds +3.3 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158162−2.5%
In funds' top 1078−12.5%
Held by funds110.4%107.0%+3.3 pts
New / increased19 / 6437 / 66−19.4%
Reduced / sold out39 / 2437 / 39−17.1%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MAZE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MAZE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$25.0M45 sales · 6 insiders
91% of the selling was under pre-arranged trading plans.
2025-12 sold $5.4M2026-01 sold $3.1M2026-02 sold $1.3M2026-03 sold $2.7M2026-04 sold $706K2026-05 sold $1.5M2026-06 sold $1.5M2026-07 sold $1.7M2026-08 sold $1.6M2026-09 sold $2.9M2026-10 sold $1.6M2026-11 sold $1.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 2Jason V ColomaCEOSale plan34,501$30.25$1.0M
Oct 29Atul DandekarCsboSale plan7,500$32.07$241K
Oct 1Jason V ColomaCEOSale plan34,501$27.02$932K
Oct 1Harold BernsteinPresident, R&D & CMOSale plan16,141$26.93$435K
Sep 29Atul DandekarCsboSale plan7,500$27.06$203K
Sep 4Harold BernsteinPresident, R&D & CMOSale plan9,705$26.22$255K
Every insider buy and sale for MAZE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MAZE insider trades →

From SEC Form 4 filings by MAZE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MAZE is in one of them and how their past MAZE trades turned out.

MAZE in the AI portfolios
Loading…

MAZE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MAZE in an article yet. Here's the latest on the wider market.

MAZE in the news

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company based in South San Francisco, California. It develops small molecule oral drugs for patients with kidney and metabolic diseases, using human genetic data to identify targets and guide development. Its most advanced candidate is in clinical trials for a genetically defined form of chronic kidney disease, and a second candidate is being prepared for trials in a metabolic disorder and chronic kidney disease. The company has no approved products, and it has partnered some of its programs with other drugmakers.

Headquarters
South San Francisco, CA